Here are relevant reports on : cancer-diagnostics-market
-
Noninvasive Cancer Diagnostics Market by Instruments (Solid Tumor, Blood Cancer, Lung Cancer, Breast Cancer), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics) - Analysis & Global Forecast to 2019
The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) & Region - Global Forecast to 2026
The global cancer diagnostics market growth is primed to transition from $17.2 billion in 2021 to $26.6 billion by 2026, showcasing a strong CAGR of 11.5%. This growth is driven by the increasing incidence of cancer and the rise in private diagnostic centers. Opportunities are enhanced by government and healthcare provider recommendations for early cancer screening.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), End-user, and Region - Global Forecast to 2029
The global cancer biomarkers market, valued at US$22.3 billion in 2023, stood at US$24.5 billion in 2024 and is projected to advance at a resilient CAGR of 11.3% from 2024 to 2029, culminating in a forecasted valuation of US$42.0 billion by the end of the period. The primary drivers of growth in this market are the rising incidence of cancer worldwide, increased research on cancer biomarkers, the growing use of biomarkers in drug discovery and development, and ongoing technical advancements.
- Published: April 2024
- Price: $ 7150
- TOC Available:
-
Cancer Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. The growth in this market is driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players. On the other hand, a low biomarker discovery-to-approval ratio and a poor regulatory and reimbursement scenario challenge the growth of the cancer profiling market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) & Region - Global Forecast to 2028
The global tissue diagnostics market, valued at US$5.2 billion in 2022, stood at US$5.6 billion in 2023 and is projected to advance at a resilient CAGR of 8.4% from 2023 to 2028, culminating in a forecasted valuation of US$8.4 billion by the end of the period. The new research study consists of an industry trend analysis of the market. Market growth is driven by the growing private diagnostic centers globally, and rising geriatric population with subsequent growth in chronic and infectious diseases.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030
The global immunohistochemistry market, valued at US$3.31 billion in 2024, stood at US$3.55 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$5.14 billion by the end of the period. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Womens Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care) & Region - Global Forecast to 2025
The global womens health diagnostics market growth is primed to transition from $25.0 billion in 2020 to $36.6 billion by 2025, showcasing a strong CAGR of 7.9%. The market growth is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Immuno Oncology Assays Market Size, Share & Trends by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026
The size of global immuno oncology assays market in terms of revenue was estimated to be worth USD 4.4 billion in 2021 and is poised to reach USD 7.9 billion by 2026, growing at a CAGR of 12.5% from 2021 to 2026. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
In Situ Hybridization Market by Offering (Consumables, Instruments, Software), Technology (FISH (DNA FISH, RNA, PNA), CISH), Application (Cancer Diagnostics, Research, Discovery), End User (Hospitals, Pharma & Biotech, Academia) - Global Forecast to 2030
The global in situ hybridization market, valued at US$1.55 billion in 2024, stood at US$1.64 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2030, culminating in a forecasted valuation of US$2.35 billion by the end of the period. The growth in the field of in situ hybridization (ISH) is significantly driven by ongoing advancements in technology, including high-sensitivity probes, automated systems, and multiplexing solutions.
- Published: June 2025
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
